Pipeline

Techulon is advancing several therapeutics toward clinical trials through an aggressive translational program. Our lead candidate is targeted at MRSA and we expect to introduce into Phase I trials by 2016. Other candidates have been identified and are currently being optimized through pre-clinical research. In particular, our pipeline is strong in Gram-negative bacteria targets.
 
Discover
Pre-clinical
IND
Phase I
 
Gram Positive (MRSA)
Gram Negative (Pseudomonas)
Gram Negative (AcB)
Gram Negative (RANT 3)